FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

vvasinigton,	D.C. 20040

OMB APPROVAL								
OMB Number:	3235-028							
Estimated average I	hurdon							

0.5 hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Harper Sean E					2. Issuer Name and Ticker or Trading Symbol AMGEN INC [AMGN]										licable)	g Person(s)	to Issuer % Owner				
															er (give title		ner (specify				
				2 0	2. Data of Faulicat Transaction (Month/Day/Mass)								\dashv	X	belov			ow)			
(Last)	(Fi	,	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 01/28/2013										EVE	EVP, Research & Developme				
ONE AMGEN CENTER DRIVE			01/	01/20/2013											,						
				. L																	
(Street)					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6.	6. Individual or Joint/Group Filing (Check Applicable						
THOUS	AND												Li	Line)							
OAKS	C.A	A S	91320-17	99											X	Form	n filed by One	e Reporting F	erson		
Ornico																		re than One I	Reporting		
-																Pers	on				
(City)	(St	ate) (Zip)																		
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																					
1. Title of S	Security (Inst	r. 3)		2. Trans	action										6. Ownershi						
				Date (Month/	Dav/Yea		Execution Date, if any			Transaction Dispose Code (Instr. 5)		l Of (D	Of (D) (Instr. 3, 4			Securi Benefi		Form: Direc (D) or Indire		of Indirect Beneficial	
		(monan/bay/rear)			(Month/Day/Year)								Owne		l Following	(I) (Instr. 4)	Ownership	Ownership			
							Code	v	Amount	(A) or		Price			ction(s)		(Instr. 4)				
								Code	Ľ	Amount	[6	(A) or (D) Prio			3 and 4)						
Common Stock 01				01/28/2013				A		7,477	7,477 ⁽¹⁾ A		\$	0 59,981 ⁽²⁾⁽³⁾		D					
		Ta	hla II - Γ) Arivat	ive S	۵۵۱۱	ritias	Δεαιιί	ired Di	ieno	sed of	or B	anafi	riall	ν Ον	hanv				_	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative	2. Conversion	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any	Date, Trai		4. Transaction				6. Date Exercisable and Expiration Date			7. Title and Amount of		8. Price of Derivative Security		9. Number o	10. Ownership		11. Nature of Indirect	
Security	or Exercise				Code (. Derivative ((Month/Day/Year)			Securities					Securities	Form:	Beneficial	ıl	
(Month/Da				ay/Year) 8)		Securities Acquired			Underlying Derivative				(Instr. 5)		Beneficially Owned	Direct (E or Indire		р			
	Security					(A) or			Security (Instr.			str. 3	3		Following Reported	(I) (Instr. 4)					
						Disposed of (D) (Instr. 3, 4 and 5)			aı			anu 4	and 4)				Transaction	(s)			
													(Instr. 4)								
				ŀ			and 5	<u> </u>				_	1.	-							
					Amoui		ount	1													
				D-4-	Numbe			nber													
					Code V (A) (D)			Date Exercisal	sable Date Title Share:		res										

Explanation of Responses:

- 1. The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 1/28/2015, 1/28/2016 and 1/28/2017, respectively.
- 2. These shares include the following RSUs granted under the Company's equity plans: 1,125 RSUs which fully vest on 4/28/2013; 2,300 RSUs which vest in two equal annual installments of 1,150 each commencing 4/26/2013; 25,000 RSUs which fully vest on 12/31/2014; 6,000 RSUs which two equal installments of 1,980 each on 4/25/2013 and 4/27/2013 and 4/27/2015 and 4/27/2015 and 4/27/2015 which vest in two equal installments of 2,855, 2,856 and 2,943 on 4/27/2015 and 4/27/2016, respectively; and 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
- 3. These shares include 117 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

01/30/2013 /s/ Sean E. Harper

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.